WHO has added the Measles Vaccine (Live) (Attenuated, Freeze-Dried) to its list of prequalified vaccines. In January 2026, WHO recommended its use for the prevention of measles in children. The vaccine is produced from prequalified bulk manufactured by PT Biofarma (Persero), Indonesia. Through a technology transfer the vaccine is filled by Biological E. Ltd., India in 5- and 10- dose presentations and has a shelf-life of 24 months at 2-80 Celsius.
The prequalification adds a third measles stand-alone vaccine to the list of PQed vaccines to ensure sufficient supply and larger access for countries to vaccinate children against measles or to be used in catch-up campaigns targeting the prevention of measles specifically. Several combination vaccines (measles, mumps, rubella and/or varicella) have also been prequalified by the WHO.